GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Enzo Biochem Inc (FRA:EZB) » Definitions » 14-Day RSI

Enzo Biochem (FRA:EZB) 14-Day RSI : 54.24 (As of Jun. 18, 2024)


View and export this data going back to 1980. Start your Free Trial

What is Enzo Biochem 14-Day RSI?

The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30.

As of today (2024-06-18), Enzo Biochem's 14-Day RSI is 54.24.

The industry rank for Enzo Biochem's 14-Day RSI or its related term are showing as below:

FRA:EZB's 14-Day RSI is ranked worse than
54.77% of 241 companies
in the Medical Diagnostics & Research industry
Industry Median: 45.08 vs FRA:EZB: 54.24

Competitive Comparison of Enzo Biochem's 14-Day RSI

For the Diagnostics & Research subindustry, Enzo Biochem's 14-Day RSI, along with its competitors' market caps and 14-Day RSI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Enzo Biochem's 14-Day RSI Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Enzo Biochem's 14-Day RSI distribution charts can be found below:

* The bar in red indicates where Enzo Biochem's 14-Day RSI falls into.



Enzo Biochem  (FRA:EZB) 14-Day RSI Calculation

The formula for calculating RSI is:

RSI=100[ 100 / ( 1 + Average Gain / Average Loss )]

* Note that the formula uses a positive value for the average loss.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Enzo Biochem  (FRA:EZB) 14-Day RSI Explanation

The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.

Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.

RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections.


Enzo Biochem 14-Day RSI Related Terms

Thank you for viewing the detailed overview of Enzo Biochem's 14-Day RSI provided by GuruFocus.com. Please click on the following links to see related term pages.


Enzo Biochem (FRA:EZB) Business Description

Traded in Other Exchanges
Address
527 Madison Avenue, New York, NY, USA, 10022
Enzo Biochem Inc is a bioscience company. The firm manufactures, develops and sell their proprietary solutions and platforms to clinical laboratories, specialty clinics and researchers and physicians internationally. It focuses on delivering and applying its technology to produce products and services to allow its customers to meet their clinical needs. The company has Enzo clinical labs, Enzo life sciences, Enzo therapeutics operating segments. It derives the majority of its revenues from the Clinical lab's segment.

Enzo Biochem (FRA:EZB) Headlines

No Headlines